N(6)-carbamoylmethyladenine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N(6)-carbamoylmethyladenine
• 英文别名: 2-(7H-purin-6-ylamino)acetamide
• 化学式: C₇H₈N₆O
• 分子量: 192.18
• InChiKey: WIFHSKZDPZUSLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N(6)-carbamoylmethyladenine 、 碘甲烷 生成 2-[(3-methylpurin-6-yl)amino]acetic acid
  参考文献：
  名称：

  FRIESEN, MARLIN D.;, GARREN LILIANE;PREVOST, VIRGINIE;SHUKER, DAVID E. G., CHEM. RES. TOXICOL., 4,(1991) N, C. 102-106

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(7H-purin-6-ylamino)acetamide;hydrochloride 、 sodium hydroxide 生成 N(6)-carbamoylmethyladenine
  参考文献：
  名称：

  FRIESEN, MARLIN D.;, GARREN LILIANE;PREVOST, VIRGINIE;SHUKER, DAVID E. G., CHEM. RES. TOXICOL., 4,(1991) N, C. 102-106

  摘要：

  DOI：

文献信息

• Compounds of chemically modified oligonucleotides and methods of use thereof
  申请人：City of Hope

  公开号：US10787664B2

  公开（公告）日：2020-09-29

  The present disclosure relates to isolated compounds including a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; method of treating diabetic nephropathy in a subject with the compounds; and method of inhibiting expression of a mammalian microRNA-379 megacluster with the compounds.

  本公开涉及分离的化合物，包括能够与哺乳动物microRNA-379转录本转录起始位点下游10至270个核碱基的RNA序列杂交的核酸序列；用这些化合物治疗受试者糖尿病肾病的方法；以及用这些化合物抑制哺乳动物microRNA-379巨簇表达的方法。
• Compounds of Chemically Modified Oligonucleotides and Methods of Use Thereof
  申请人：City of Hope

  公开号：US20160348105A1

  公开（公告）日：2016-12-01

  The present disclosure relates to isolated compounds including a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; method of treating diabetic nephropathy in a subject with the compounds; and method of inhibiting expression of a mammalian microRNA-379 megacluster with the compounds.
• COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
  申请人：City of Hope

  公开号：US20200407721A1

  公开（公告）日：2020-12-31

  The present disclosure relates to isolated compounds including a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; method of treating diabetic nephropathy in a subject with the compounds; and method of inhibiting expression of a mammalian microRNA-379 megacluster with the compounds.
• COMPLEMENTARY RNA LINKED BISPECIFIC T-CELL ENGAGING ANTIBODIES
  申请人：City of Hope

  公开号：US20220119552A1

  公开（公告）日：2022-04-21

  The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides. Two antibodies are capable of forming complexes in vivo through hybridization of the respective complementary oligoribonucleotides they are bound to. For example, a first antibody bound to a first oligoribonucleotide through a first chemical linker may be administered to a subject, bind to a cell surface antigen in vivo and subsequently form an antibody complex in vivo with a second antibody bound to a second oligoribonucleotide through a second chemical linker, through complementary base-pairing between the first and the second oligoribonucleotide. The compositions and methods provided herein are, inter alia, useful for diagnostic and therapeutic purposes, for example, the treatment of cancer or autoimmune disease.
• [EN] COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS D'OLIGONUCLÉOTIDES MODIFIÉS CHIMIQUEMENT ET LEURS MÉTHODES D'UTILISATION
  申请人：HOPE CITY

  公开号：WO2020037254A1

  公开（公告）日：2020-02-20

  The present disclosure relates to isolated compounds including a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; methods of treating a condition of a subject (e.g., diabetes, obesity, or complications thereof) with the compounds; and methods of inhibiting expression of a mammalian microRNA-379 megacluster with the compounds.